Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date: April 17, 2013
Purpose: This filing supplements and corrects specific disclosures in the definitive proxy statement (Schedule 14A) filed on April 30, 2012. The company states these corrections do not indicate material misstatements in the original proxy statement.
Key Financial Metrics and Disclosures
This filing does not report operational financial results (revenue, profit, cash flow) for a specific period. Instead, it corrects historical financial and compensation data previously disclosed for fiscal year 2011 and the period ending March 31, 2012:
- Audit Fees (FY 2011): Corrected from $70,327 (cash paid in 2011) to $196,327 (total fees for FY 2011, including amounts paid in 2012).
- Accrued Management Incentive: Corrected from approximately $325,000 to $336,000 for the period August 1, 2011, to March 31, 2012.
- Executive Compensation (2011): Michael Gennaro's compensation corrected from $215,850 to $215,691.
Material Changes and Corrections
The filing details the following specific corrections to prior disclosures:
- Executive Employment Agreements: Clarified that Dr. Kazuko Matsuda, promoted to executive officer in September 2011, does not have an executive employment agreement in place, contrary to prior general disclosure.
- Compensation Committee Meetings: Corrected the number of meetings held in 2011 from seven to eight.
- Stock Options: Corrected the number of unexercised exercisable stock options for Dr. Kirk Johnson expiring January 31, 2020, from 40,833 shares to 45,833 shares.
Guidance, Outlook, and Risks
The filing contains no new guidance, outlook, or management commentary regarding future business performance. It explicitly states that no other changes are being made to the Proxy Statement and that the corrections do not imply the original statement contained material misstatements.
Investor Verification Checklist
- Verify the total audit fees paid to Ernst & Young for fiscal year 2011 ($196,327) versus the cash paid in 2011 ($70,327).
- Confirm the absence of an executive employment agreement for Dr. Kazuko Matsuda.
- Review the corrected stock option count for Dr. Kirk Johnson (45,833 shares).
- Check the corrected accrued discretionary management cash incentive figure ($336,000).